16.31
-1.62 (-9.01%)
| Previous Close | 17.93 |
| Open | 17.07 |
| Volume | 116,089 |
| Avg. Volume (3M) | 68,143 |
| Market Cap | 3,087,874,304 |
| Price / Earnings (Forward) | 56.82 |
| Price / Sales | 4.67 |
| Price / Book | 2.25 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Profit Margin | 5.99% |
| Operating Margin (TTM) | -4.99% |
| Diluted EPS (TTM) | 0.200 |
| Quarterly Revenue Growth (YOY) | 6.40% |
| Quarterly Earnings Growth (YOY) | -84.70% |
| Total Debt/Equity (MRQ) | 11.64% |
| Current Ratio (MRQ) | 2.83 |
| Operating Cash Flow (TTM) | -46.98 M |
| Levered Free Cash Flow (TTM) | -50.75 M |
| Return on Assets (TTM) | -2.14% |
| Return on Equity (TTM) | 5.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | HUTCHMED (China) Limited | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Value |
| % Held by Insiders | 0.12% |
| % Held by Institutions | 3.87% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (B of A Securities, 71.67%) | Buy |
| Median | 20.88 (28.02%) | |
| Low | 13.75 (Morgan Stanley, -15.70%) | Sell |
| Average | 20.88 (28.02%) | |
| Total | 1 Buy, 1 Sell | |
| Avg. Price @ Call | 17.17 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 22 Sep 2025 | 13.75 (-15.70%) | Sell | 16.66 |
| B of A Securities | 22 Jul 2025 | 28.00 (71.67%) | Buy | 17.68 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Oct 2025 | Announcement | HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025 |
| 11 Sep 2025 | Announcement | Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025 |
| 04 Sep 2025 | Announcement | HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 |
| 24 Aug 2025 | Announcement | HUTCHMED Announces Appointment of Acting Chief Executive Officer |
| 19 Aug 2025 | Announcement | HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China |
| 07 Aug 2025 | Announcement | HUTCHMED Reports 2025 Interim Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |